Cardiology news - 2019-Sept-10

Cardiology: SGLT-2 inhibitor dapagliflozin shown to reduce cardiovascular death in patients with heart failure with reduced ejection fraction regardless of diabetes status - https://www.acc.org/latest-in-cardiology/clinical-trials/2019/08/30/21/33/dapa-hf